Dianthus Therapeutics, Inc. (DNTH)
82.37
-0.06
(-0.07%)
USD |
NASDAQ |
Oct 09, 16:00
83.00
+0.63
(+0.76%)
After-Hours: 20:00
Dianthus Therapeutics Net Income (Quarterly) : -50.22M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -50.22M |
| March 31, 2026 | -40.83M |
| December 31, 2025 | -64.43M |
| September 30, 2025 | -36.76M |
| June 30, 2025 | -31.63M |
| March 31, 2025 | -29.51M |
| December 31, 2024 | -28.44M |
| September 30, 2024 | -25.17M |
| June 30, 2024 | -17.61M |
| March 31, 2024 | -13.75M |
| December 31, 2023 | -10.56M |
| September 30, 2023 | -14.76M |
| June 30, 2023 | -11.14M |
| March 31, 2023 | -7.089M |
| December 31, 2022 | -10.12M |
| September 30, 2022 | -7.784M |
| June 30, 2022 | -17.27M |
| March 31, 2022 | -22.95M |
| December 31, 2021 | -19.29M |
| Date | Value |
|---|---|
| September 30, 2021 | -17.43M |
| June 30, 2021 | -16.93M |
| March 31, 2021 | -17.49M |
| December 31, 2020 | -18.17M |
| September 30, 2020 | -17.68M |
| June 30, 2020 | -19.08M |
| March 31, 2020 | -20.01M |
| December 31, 2019 | -23.24M |
| September 30, 2019 | -20.99M |
| June 30, 2019 | -17.71M |
| March 31, 2019 | -14.83M |
| December 31, 2018 | -16.68M |
| September 30, 2018 | -16.02M |
| June 30, 2018 | -13.66M |
| March 31, 2018 | -11.16M |
| December 31, 2017 | -8.036M |
| September 30, 2017 | -6.913M |
| June 30, 2017 | -15.73M |
| March 31, 2017 | -4.811M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Verastem, Inc. | -34.67M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.761M |
| Total Expenses (Quarterly) | 50.98M |
| EPS Diluted (Quarterly) | -0.8962 |
| Enterprise Value | 3.628B |
| Gross Profit Margin (Quarterly) | 85.94% |
| Profit Margin (Quarterly) | -6.60K% |
| Earnings Yield | -5.04% |
| Normalized Earnings Yield | -5.040 |